Initial Therapy
Target Agent(s) will be approved when ALL of the following are met:
ALL of the following
ONE of the following
A. Continuation of therapy
The requested agent is eligible for continuation of therapy.
The prescriber states that the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.
B. Initial therapy
ALL of the following
The patient has a diagnosis of one of the following relapsing forms of multiple sclerosis (MS): relapsing-remitting disease (RRMS) or active secondary progressive disease (SPMS).
ONE of the following
ALL of the following
The patient has highly active MS disease activity.
ONE of the following
Greater than or equal to 2 relapses in the previous year.
ANY of the following
Greater than or equal to 1 gadolinium-enhancing lesion on MRI.
A significant increase in T2 lesion load compared with a previous MRI.
The patient has been treated with 3 disease-modifying therapies (DMTs) from different drug classes.
The patient has another FDA-labeled indication for the requested agent and route of administration.
The patient has an indication supported in compendia for the requested agent and route of administration.
If the patient has an FDA-labeled indication, ONE of the following
The patient's age is within FDA labeling for the requested indication for the requested agent.
There is support for using the requested agent for the patient's age for the requested indication.
The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
The patient does NOT have any FDA-labeled contraindications to the requested agent.
If the patient has been previously treated with the requested agent, the patient has NOT received a prior course with the requested agent within the past 12 months.
Continuation Therapy
Target Agent(s) will be approved when ALL of the following are met:
ALL of the following
The patient has been previously approved for the requested agent through the plan's Prior Authorization process.
Patients not previously approved for the requested agent require initial evaluation review.
The patient has had clinical benefit with the requested agent.
The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
The patient has NOT received a prior course with the requested agent within the past 12 months.
The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
Initial Therapy — Continuation Eligibility or Alternative Clinical Pathway
Target Agent(s) will be approved when ALL of the following are met:
ALL of the following
ONE of the following
A. Continuation of therapy
The requested agent is eligible for continuation of therapy.
The prescriber states that the patient has been treated with the requested agent within the past 210 days and is at risk if therapy is changed.
B. Alternative clinical pathway
ONE of the following
The patient has a diagnosis of a relapsing form of multiple sclerosis (MS).
Continuation and Renewal Therapy
Target Agent(s) will be approved when ALL of the following are met:
ALL of the following
The patient has been previously approved for the requested agent through the plan's Prior Authorization process.
Patients not previously approved for the requested agent require initial evaluation review.
The patient has had clinical benefit from treatment with the requested agent.
The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
The patient will NOT be using the requested agent in combination with another disease-modifying therapy (DMT) per the Disease Modifying Therapies list.
The patient does NOT have any FDA-labeled contraindications to the requested agent.
Quantity-Limit Approval Criteria
Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:
ONE of the following
The requested quantity (dose) does NOT exceed the program quantity limit.
ALL of the following
The requested quantity (dose) exceeds the program quantity limit.
ONE of the following
ALL of the following
The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
Coverage is excluded when the requested agent will be used in combination with another disease-modifying therapy (DMT) listed in the Disease Modifying Therapies list.
Coverage is excluded when the patient has an FDA-labeled contraindication to the requested agent.
Coverage is excluded if the patient received a prior course of the requested agent within the past 12 months.
Continuation or renewal coverage is excluded when the requested agent will be used in combination with another disease-modifying therapy (DMT) listed in the Disease Modifying Therapies list.
Continuation or renewal coverage is excluded when the patient has an FDA-labeled contraindication to the requested agent.
Concomitant use of multiple sclerosis disease-modifying therapies with listed immunomodulatory agents is contraindicated. Listed agents include Abrilada (adalimumab-afzb), Actemra (tocilizumab), Adalimumab, Adbry (tralokinumab-ldrm), Amjevita (adalimumab-atto), Anzupgo (delgocitinib), Arcalyst (rilonacept), Avsola (infliximab-axxq), Avtozma (tocilizumab-anoh), Tysabri (natalizumab), Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), and Zeposia (ozanimod).
Concomitant therapy involving the listed contraindicated immunomodulatory agents is excluded. The list includes Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), and Zeposia (ozanimod).
The listed immunomodulatory agents must not be used concomitantly with the requested multiple sclerosis disease-modifying therapy.